BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.33.0//EN
X-ORIGINAL-URL:https://www.igf.cnrs.fr/
X-WR-CALNAME:IGF
X-WR-CALDESC:Institut de génomique fonctionnelle
X-WR-TIMEZONE:Europe/Paris
BEGIN:VTIMEZONE
TZID:Europe/Paris
X-LIC-LOCATION:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=4SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-90ef635b07e4335585e9aa6c7d742e94@igf.cnrs.fr
DTSTART;TZID=Europe/Paris:20260424T110000
DTEND;TZID=Europe/Paris:20260424T120000
DTSTAMP:20260319T113301Z
CREATED:20260319
LAST-MODIFIED:20260319
PRIORITY:5
SEQUENCE:2
TRANSP:OPAQUE
SUMMARY:Seminar – Ramaroson ANDRIANTSITOHAINA
DESCRIPTION:Extracellular Vesicles‑Guided Delivery and NLRP3 Blockade: A Hypothalamic Therapeutic Roadmap for Atherosclerosis and Atrial Fibrillation\nWith more than 25 years of pioneering leadership in extracellular vesicle (EV) biology, Ramaroson Andriantsitohaina is internationally recognized for advancing EVs into powerful tools for understanding and treating cardiometabolic diseases. His work has helped establish EVs as biomarkers, intercellular communication vectors, and next‑generation biotherapeutics.\nHe integrates world‑class EV profiling in both animal models and human cohorts with the development of patented EV-based therapeutic platforms, including an innovative neuron‑targeted suppression system. His access to large, deeply phenotyped human plasma cohorts enables the rapid translation of mechanistic EV signatures into early diagnostic strategies and precision therapies, bridging fundamental discovery to clinical application.\nA leading figure in cardiovascular and metabolic research, Ramaroson Andriantsitohaina has shaped the field through high‑impact translational contributions, including patents, clinical studies, and the coordination of major cohorts. He previously served as Director of UMR INSERM 1063 Angers Stress Oxydant et Pathologies Métaboliques and as Director of the Structure Fédérative de Recherche ICAT 4208 Interactions Cellulaires et Applications Thérapeutiques.\n
URL:https://www.igf.cnrs.fr/en/events/seminar-mike-hildebrand-863/
CATEGORIES:Seminars
ATTACH;FMTTYPE=image/png:https://www.igf.cnrs.fr/wp-content/uploads/2026/03/Ramaroson.png
END:VEVENT
END:VCALENDAR